Audentes CEO exits as Astellas rebrands a gene therapy buyout
Dive Brief: Natalie Holles, the chief executive of Audentes Therapeutics, has departed the company as the gene therapy developer's new owner Astellas Pharma fully folds the biotech into its larger organization. Audentes, which was acquired by Astellas for $3 billion almost a year and a half ago, will now operate under the name Astellas Gene Therapies, the company announced Wednesday. All 350 Audentes employees will join the newly formed unit, but Holles and "some members" of the Audentes leadership team will not transition over, an Astellas spokesperson confirmed to BioPharma Dive. Dive Insig...